Share ownership Iqvia Holdings Inc.

IQV

US46266C1053

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 18:05:20 10/04/2026 BST			5-day change	1st Jan Change
166.13 ^USD	-1.69%		-2.30%	-26.00%

04-09	Glenmark Pharmaceuticals Limited Receives U.S. FDA Approval for Progesterone Vaginal Inserts, 100 Mg	CI
04-09	Glenmark Pharma Gets US FDA Final Nod for Progesterone Vaginal Inserts	MT

Share class: Iqvia Holdings Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	258,200,000	174,409,440 ( 67.55 %)	82,100,000 ( 31.8 %)	67.55 %

Major shareholders: Iqvia Holdings Inc.

Name	Equities	%	Valuation
Vanguard Fiduciary Trust Co. 11.58 %	19,650,532	11.58 %	3 514 M $
Harris Associates LP 6.67 %	11,319,718	6.67 %	2 024 M $
BlackRock Advisors LLC 5.947 %	10,092,524	5.947 %	1 805 M $
STATE STREET CORPORATION 4.388 %	7,446,912	4.388 %	1 332 M $
GIC Pte Ltd. (Investment Management) 3.855 %	6,541,387	3.855 %	1 170 M $
Geode Capital Management LLC 2.578 %	4,374,971	2.578 %	782 M $
Boston Partners Global Investors, Inc. 2.409 %	4,087,380	2.409 %	731 M $
JPMorgan Investment Management, Inc. 2.239 %	3,799,600	2.239 %	679 M $
BlackRock Life Ltd. 2.088 %	3,543,744	2.088 %	634 M $
Fidelity Management & Research Co. LLC 2.05 %	3,478,255	2.05 %	622 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	82.51%
Other	11.68%
State Street Corp.	4.39%
Individuals	0.96%
Sumitomo Mitsui Trust Group, Inc.	0.67%
Manulife Financial Corp.	0.31%
Schweizerische Nationalbank	0.27%
Governments	0.15%
Skandinaviska Enskilda Banken AB	0.13%
Associated Banc-Corp	0.1%
Polar Capital Holdings Plc	0.09%
SEI Investments Co.	0.09%
Danske Bank A/S	0.05%
Swedbank AB	0.05%
Markel Group, Inc.	0.03%
The Bank of Nova Scotia	0.02%
Fifth Third Bancorp	0.01%
Regions Financial Corp.	0.01%
Münchener Rückversicherungs-Gesellschaft AG	0.01%
The Allstate Corp.	0.01%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	73.23%
United Kingdom	9.19%
Singapore	4.03%
Canada	3.73%
Norway	1.4%
Japan	1.14%
Bermuda	1.13%
Australia	1.06%
Individuals	0.96%
Austria	0.69%
Sweden	0.63%
Denmark	0.59%
Luxembourg	0.54%
Switzerland	0.53%
France	0.5%
Belgium	0.46%
Netherlands	0.43%
Germany	0.25%
South Korea	0.24%
Ireland	0.22%
New Zealand	0.14%
Finland	0.11%
Spain	0.06%
Italy	0.06%
South Africa	0.06%
Hong Kong	0.04%
Czech Republic	0.03%
Mexico	0.03%
Slovenia	0.02%
Cayman Islands	0.01%
India	0.01%
United Arab Emirates	0.01%
China	0.01%

Based on 1000 largest holdings

Iqvia Holdings Inc. is one of the world's leading companies specializing in information, analytics, research and healthcare services based on technology solutions. Net sales break down by activity as follows: - development of contract research and clinical development solutions and services (54.5%): helping biopharmaceutical companies, medical researchers and healthcare professionals optimize their clinical studies, develop new therapeutic classes, identify treatment needs and assess the efficacy of pharmaceuticals with a view to improving clinical and scientific outcomes; - development of technology and analytics solutions (40.6%): services related to information, analysis, strategic consulting, marketing studies and short-term healthcare-market studies, business processes outsourcing, and management of medical-administrative databases, all aimed at optimizing the performance and commercial strategies of pharmaceutical companies and health workers; - integrated services (4.9%): development and implementation of customized solutions and customer engagement programs, healthcare services, scientific and medical services, etc. Net sales are distributed geographically as follows: Americas (47.5%), Europe and Africa (31.8%) and Asia/Pacific (20.7%).

Employees

93,000

Sector

Biotechnology & Medical Research

More about the company